ED Initiated Oral Naltrexone for AUD

  • End date
    Mar 24, 2023
  • participants needed
  • sponsor
    Icahn School of Medicine at Mount Sinai
Updated on 24 March 2022


This study will recruit Emergency Department (ED) patients with moderate to severe alcohol use disorder (AUD) who are interested in initiating medication assisted treatment (MAT). The study is split into two phases. The first phase (N=10) will use implementation science strategies to strengthen existing non-targeted ED based AUD screening program and optimize feasibility, acceptability, and linkage pathways. The second phase (N=20) will incorporate lessons learned from phase 1 to initiate ED patients on MAT for AUD in the form of oral naltrexone. The primary outcome for both phase 1 and phase 2 is engagement in comprehensive addiction treatment at 14 and 30 days post enrollment.



The study will be comprised of two components outlined below:

  1. Site Implementation Component

In this component implementation science strategies will be used to strengthen existing non-targeted ED based AUD screening program and optimize feasibility, acceptability and linkage pathways. Three specific aims are to, 1) optimize registered nurse (RN) driven non-targeted alcohol use screening supplemented with secondary screening using DSM-5 criteria for AUD and an SBIRT (screening, brief intervention and referral to treatment) intervention administered by trained staff. 2) During a 3-month period, use continuous quality improvement methods to decrease the time for completion of AUD screening to an interval that is acceptable to ED patients and ED providers and 3) Assess willingness to initiate oral naltrexone among ED patients with moderate to severe AUD. Ten (10) patients will be enrolled in phase 1.

2. Oral Naltrexone Feasibility Component

In this component the study team aims to assess the feasibility of initiating treatment in ED patients with moderate to severe AUD on oral naltrexone, an evidence based and accepted standard of care treatment for AUD. Specifically, 1) over an 8-month period the study team aims to identify 20 patients with moderate to severe AUD eligible and interested in immediate initiation of oral naltrexone. Consenting patients will be receive a standard SBIRT intervention and be provided with immediate oral naltrexone initiation in the ED with a 14-day starter pack at the time of ED discharge. All participants will receive facilitated linkage to comprehensive out-patient care. 2) The study team aims will evaluate the impact of immediate ED initiated oral naltrexone with the primary outcome being engagement in comprehensive addiction care at 14 and 30 days post enrollment. Secondary outcomes include medication adherence, changes in daily alcohol consumption, number of heavy drinking days, hospital admissions and ED utilization, transition to long-acting injectable naltrexone and alcohol craving. 3) Lastly, the study team will collect data on recruitment and attrition rates, as well as means and standard deviations for key measures that will be needed to plan a definitive randomized controlled trial of ED-initiated oral naltrexone.

Condition Alcohol Use Disorder
Treatment Emergency Department Initiated Oral Naltrexone
Clinical Study IdentifierNCT04817410
SponsorIcahn School of Medicine at Mount Sinai
Last Modified on24 March 2022


Yes No Not Sure

Inclusion Criteria

Emergency Department patients 18 years of age or older
Treated in the ED during screening hours
Moderate to severe AUD as determined by DSM-5 criteria
Able to speak and understand English
Medically stable for an interview as determined by their primary ED provider
Willing and able to consent to study participation
Two points of contact available for follow-up

Exclusion Criteria

ED patients younger than 18 years of age
Medically or psychiatrically unstable as determined by the ED provider
Unable to speak or understand English
Unable to provide consent for study participation
Past year opioid dependence
Urine drug screen positive for opioids
Current or anticipated need for opioid medications for pain
Anticipated surgical procedure within 14-day of ED visit
Serologic evidence of liver disease (LFTs 3X normal) within 7 days of enrollment
Cirrhosis either by PMH or self-report
Pregnant or breastfeeding
Lacking contact information for follow-up
Requiring in-patient admission for medical or psychiatric reasons
Patient receiving a sexual assault forensics exam (SAFE)
Patient suspected of having COVID-19
Patient is actively suicidal or homicidal
Previously enrolled in either the implementation or feasibility phase of the study
Be a prisoner or in police custody at the time of the index ED visit
Be currently (anytime within the last 14 days) enrolled in formal addiction treatment, including by court order
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note